What is Thermo Fisher Scientific's role in US pharmaceutical reshoring?

Thermo Fisher's pharmaceutical services business is winning contracts to help clients move manufacturing production from Europe and Asia to the U.S.

Why are companies reshoring pharmaceutical production to the US?

Policies, including potential tariffs on imported medicines, have prompted pharmaceutical companies to shift manufacturing back to the United States.

How is the biotech funding landscape looking according to Thermo Fisher's CEO?

Thermo Fisher's CEO, Marc Casper, indicated that biotech funding is improving, leading to increased confidence in investing in pharmaceutical pipelines.

Home / Business and Economy / Thermo Fisher Wins Contracts as Companies Shift Pharma Production to US

Thermo Fisher Wins Contracts as Companies Shift Pharma Production to US

14 Jan

•

Summary

Thermo Fisher's pharmaceutical services are securing contracts for US production relocation.
CEO cites a significant focus on reshoring pharmaceutical manufacturing to the US.
Biotech funding is improving, fostering confidence in R&D investment.

Thermo Fisher Wins Contracts as Companies Shift Pharma Production to US

Thermo Fisher Scientific's pharmaceutical services division is experiencing a surge in contracts as companies actively reshore their manufacturing operations back to the United States. CEO Marc Casper stated that there is a significant drive to bring production and related activities domestically. This trend is anticipated to provide a substantial boost to the company's business in 2027 and 2028.

Casper mentioned that the acquisition of Sanofi's manufacturing site in Ridgefield, New Jersey, was partly to accommodate this expansion of capital. This move is designed to assist clients in relocating their production facilities. The company's executive also expressed optimism regarding the state of biotech funding, suggesting an improved environment for investment in research and development pipelines.